PMID- 33187214
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Nov 11
TI  - The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy 
      in Cancer Treatment.
LID - 10.3390/cancers12113332 [doi]
LID - 3332
AB  - Lonidamine (LND) has the ability to resist spermatogenesis and was first used as 
      an anti-spermatogenic agent. Later, it was found that LND has a degree of 
      anticancer activity. Currently, LND is known to target energy metabolism, mainly 
      involving the inhibition of monocarboxylate transporter (MCT), mitochondrial 
      pyruvate carrier (MPC), respiratory chain complex I/II, mitochondrial 
      permeability transition (PT) pore, and hexokinase II (HK-II). However, phase II 
      clinical studies showed that LND alone had a weak therapeutic effect, and the 
      effect was short and reversible. Interestingly, LND does not have the common side 
      effects of traditional chemotherapeutic drugs, such as alopecia and 
      myelosuppression. In addition, LND has selective activity toward various tumors, 
      and its toxic and side effects do not overlap when combined with other 
      chemotherapeutic drugs. Therefore, LND is commonly used as a chemosensitizer to 
      enhance the antitumor effects of chemotherapeutic drugs based on its disruption 
      of energy metabolism relating to chemo- or radioresistance. In this review, we 
      summarized the combination treatments of LND with several typical 
      chemotherapeutic drugs and several common physical therapies, such as 
      radiotherapy (RT), hyperthermia (HT), and photodynamic therapy (PDT), and 
      discussed the underlying mechanisms of action. Meanwhile, the development of 
      novel formulations of LND in recent years and the research progress of LND 
      derivative adjudin (ADD) as an anticancer drug were also discussed.
FAU - Huang, Yaxin
AU  - Huang Y
AD  - Beijing Key Laboratory of Environment and Viral Oncology, College of Life Science 
      and Chemistry, Faculty of Environment and Life, Beijing University of Technology, 
      Beijing 100124, China.
FAU - Sun, Guohui
AU  - Sun G
AUID- ORCID: 0000-0003-2259-5431
AD  - Beijing Key Laboratory of Environment and Viral Oncology, College of Life Science 
      and Chemistry, Faculty of Environment and Life, Beijing University of Technology, 
      Beijing 100124, China.
FAU - Sun, Xiaodong
AU  - Sun X
AD  - Beijing Key Laboratory of Environment and Viral Oncology, College of Life Science 
      and Chemistry, Faculty of Environment and Life, Beijing University of Technology, 
      Beijing 100124, China.
FAU - Li, Feifan
AU  - Li F
AD  - Beijing Key Laboratory of Environment and Viral Oncology, College of Life Science 
      and Chemistry, Faculty of Environment and Life, Beijing University of Technology, 
      Beijing 100124, China.
FAU - Zhao, Lijiao
AU  - Zhao L
AUID- ORCID: 0000-0002-4876-323X
AD  - Beijing Key Laboratory of Environment and Viral Oncology, College of Life Science 
      and Chemistry, Faculty of Environment and Life, Beijing University of Technology, 
      Beijing 100124, China.
FAU - Zhong, Rugang
AU  - Zhong R
AD  - Beijing Key Laboratory of Environment and Viral Oncology, College of Life Science 
      and Chemistry, Faculty of Environment and Life, Beijing University of Technology, 
      Beijing 100124, China.
FAU - Peng, Yongzhen
AU  - Peng Y
AD  - National Engineering Laboratory for Advanced Municipal Wastewater Treatment & 
      Reuse Technology, Engineering Research Center of Beijing, Beijing University of 
      Technology, Beijing 100124, China.
LA  - eng
GR  - 82003599/National Natural Science Foundation of China/
GR  - 21778011/National Natural Science Foundation of China/
GR  - KM202110005005/Science and Technology General Project of Beijing Municipal 
      Education Commission/
GR  - 7184192/Beijing Natural Science Foundation/
GR  - 2018-ZZ-022/Beijing Postdoctoral Research Foundation/
GR  - ZZ2019-30/Beijing Postdoctoral Research Foundation/
GR  - CIT&TCD20180308/the Great Wall Scholars Program of Beijing Municipal Education 
      Commission/
GR  - PXM2015_014204_500175/Science and Technology Key Project of Beijing Municipal 
      Education Commission/
PT  - Journal Article
PT  - Review
DEP - 20201111
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7696079
OTO - NOTNLM
OT  - Lonidamine
OT  - chemotherapy
OT  - combination
OT  - energy metabolism
OT  - physical therapy
OT  - resistance
COIS- The authors declare no conflict of interest.
EDAT- 2020/11/15 06:00
MHDA- 2020/11/15 06:01
PMCR- 2020/11/11
CRDT- 2020/11/14 01:03
PHST- 2020/10/30 00:00 [received]
PHST- 2020/11/09 00:00 [accepted]
PHST- 2020/11/14 01:03 [entrez]
PHST- 2020/11/15 06:00 [pubmed]
PHST- 2020/11/15 06:01 [medline]
PHST- 2020/11/11 00:00 [pmc-release]
AID - cancers12113332 [pii]
AID - cancers-12-03332 [pii]
AID - 10.3390/cancers12113332 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Nov 11;12(11):3332. doi: 10.3390/cancers12113332.